Financial Incentives for Smoking Treatment II

Summary

Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.

Conditions

• Smoking Cessation
• Tobacco Use Cessation

Interventions

BEHAVIORAL

Smoking cessation counseling (Quitline)

Quitline offers community-based counseling session with a cessation counselor.

BEHAVIORAL

Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)

Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.

BEHAVIORAL

Financial incentives for smoking cessation

Participants will receive financial incentives for bioconfirmed smoking cessation.

BEHAVIORAL

Financial incentives for use of evidence-based smoking cessation therapies

Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies

Sponsors & Collaborators

• NYU Langone Health

  collaborator OTHER

• Olive View-UCLA Education & Research Institute

  collaborator OTHER

• University of California, Los Angeles

  lead OTHER

Principal Investigators

• Joseph Ladapo, MD, PhD · University of California, Los Angeles

• Scott Sherman, MD · NYU Langone Health

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-01-06

Primary Completion

2025-04-07

Completion

2027-06-30

Countries

• United States

Study Locations